trial

Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

NCTId NCT04506905
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 63 (actual)
Sponsored by Merck Sharp & Dohme LLC
Primary completion 2022-03-22
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
63 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2020-08-28
Primary completion
2022-03-22
Eligibility
ALL · 18 Years · 80 Years

Interventions & indications

Drugs
Elpipodect

Sponsors

Merck Sharp & Dohme LLCLead Sponsor

Sites

6 total
Rogers, United StatesGlendale, United StatesLong Beach, United StatesHallandale, United StatesOakland Park, United StatesBerlin, United States

Facts & assertions

4 sourced
Enrollment
63
Phase
PHASE1
Primary Completion Date
2022-03-22
Status
COMPLETED
relationships
The graph out of here
drug
Elpipodect
drug
lead_sponsor
Merck Sharp & Dohme LLC
company
indication
Schizophrenia
indication
Schizophrenia
indication